Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205779 | 0.84 | HRH2 (0.49) | MAPTALDH1A1HPGDSMN1; SMN2HRH2 | |
| SCHEMBL5203370 | 0.84 | HRH2 (0.47) | MAPTALDH1A1HRH2HTR2AHTR2C | |
| SCHEMBL4852934 | 0.84 | HRH2 (0.50) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4859761 | 0.83 | HRH2 (0.48) | MAPTHRH2HTR2AHTR2CHTR2B | |
| SCHEMBL5204486 | 0.82 | MAPT (0.54) | MAPTALDH1A1RAB9ASMN1; SMN2HRH2 | |
| SCHEMBL5202293 | 0.82 | THRB (0.49) | MAPTALDH1A1HRH2HTR2AHTR2C | |
| SCHEMBL4857600 | 0.81 | HTR2A (0.49) | MAPTALDH1A1HRH2HTR2AHTR2C | |
| SCHEMBL5202181 | 0.79 | HRH2 (0.49) | MAPTHRH2HTR2AHTR2CHTR2B | |
| SCHEMBL5203382 | 0.78 | MAPT (0.46) | MAPTALDH1A1SMN1; SMN2HRH2HTR2A | |
| SCHEMBL5204484 | 0.78 | SLC2A1 (0.47) | MAPTALDH1A1HRH2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| US-7368470-B2 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | OPRD1, OPRK1, TPH1 | MAPT 890/4885ALDH1A1 755/4885NPC1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.